ABVC BIOPHARMA INC (ABVC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.96-3.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ABVC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 26.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
ABVC — dividend update
Dated 2026-08-27
Entry into a Material Definitive Agreement On August 21, 2026, ABVC BioPharma, Inc. (the “ Company ”) completed the previously announced partial legal and structural separation (the “ Reorganization Transactions ”) of its subsidiary, BioKey (Cayman), Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (“ BioKey Cayman ”), by distributing approximately 15% of the issued and outstanding ordinary shares, par value $0.0001 per share (“ Ordinary Share…
Why it matters: This distribution could change how investors feel and affect company cash.
Watch forThe BioKey share distribution will finish on August 21, 2026.
Also watch forThere are more delays or issues with the BioKey share distribution.
Why it matters: The share distribution outcome can change investor feelings. It can also affect stock liquidity.
Watch forThe delayed share distribution will happen on August 21, 2026, as planned.
Also watch forThe share distribution is delayed again or canceled.
Why it matters: Changes in auditors can change the quality of financial reports. This may affect investor trust and stock performance.
Watch forQ2 2026 results show clearer financial reporting and no major issues.
Also watch forQ2 2026 results show problems linked to the new auditor.
Why it matters: A new auditor can change financial reports. It might show problems inside the company.
Worry ifKreit & Chiu CPA LLP is confirmed as the new auditor for the fiscal year.
Less concerning ifIf the transition goes well, financial reports stay steady.
Why it matters: The change in auditors can affect financial reporting and investor trust. It's important to monitor.
Worry ifThe new accounting firm reports no significant issues in the first audit.
Less concerning ifThe new accounting firm finds big problems or delays in reporting.
Why it matters: Reducing operating losses is key to financial health. It shows management is controlling costs.
Supportive ifOperating losses drop to less than negative $700,000 in Q3 2026.
Worry ifOperating losses rise back above negative $800,000 in Q3 2026.
Why it matters: Changes in auditors can affect how investors feel and how clear financial reports are.
Watch forPositive commentary on the transition to Kreit & Chiu CPA LLP in future filings.
Also watch forThere were problems reported with Kreit & Chiu CPA LLP's audit process.
Why it matters: Increasing licensing revenue shows progress in partnerships. This can boost overall growth.
Supportive ifLicensing revenue exceeds $1.5 million in Q3 2026.
Worry ifLicensing revenue stays below $1.28 million in Q3 2026.
Why it matters: Better cash flow shows the company is managing its finances well. This can attract more investors.
Supportive ifCash from operations improves to less negative than $200,000 in Q3 2026.
Worry ifCash from operations stays more negative than $244,413 in Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$361 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $774 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,839 loss on $10,000 · 78.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.